These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 1081857

  • 21. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B.
    Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453
    [Abstract] [Full Text] [Related]

  • 22. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K.
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [Abstract] [Full Text] [Related]

  • 23. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S, Benseler SM, Kirby-Allen M, Silverman ED.
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [Abstract] [Full Text] [Related]

  • 24. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.
    Toubi E, Kessel A, Shoenfeld Y.
    Hum Immunol; 2005 Apr; 66(4):395-402. PubMed ID: 15866703
    [Abstract] [Full Text] [Related]

  • 25. Pathophysiology and pharmacology of systemic lupus erythematosus.
    Schneider M.
    J Physiol Pharmacol; 1993 Sep; 44(3):187-97. PubMed ID: 8241523
    [Abstract] [Full Text] [Related]

  • 26. Levamisole in the treatment of systemic lupus erythematosus--preliminary results.
    Feng PH, Oon CJ, Yo SL, Lau YK.
    Singapore Med J; 1978 Sep; 19(3):120-4. PubMed ID: 751195
    [No Abstract] [Full Text] [Related]

  • 27. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 28. Effects of lymphocytotoxins of systemic lupus erythematosus (SLE) sera on T and B lymphocytes.
    Gergely P, Szegedi G, Szabó G, Fekete B, Petrányi G.
    Acta Med Acad Sci Hung; 1975 May; 32(1):43-8. PubMed ID: 1086049
    [Abstract] [Full Text] [Related]

  • 29. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
    Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA.
    Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
    [Abstract] [Full Text] [Related]

  • 30. Favourable interactions of cytostatic and steroid drugs in treatment of systemic lupus erythematosus.
    Wiewiórowski M, Graczyk J.
    Acta Pol Pharm; 2000 Nov; 57 Suppl():92-5. PubMed ID: 11293279
    [Abstract] [Full Text] [Related]

  • 31. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus.
    Bruns A, Bläss S, Hausdorf G, Burmester GR, Hiepe F.
    Arthritis Rheum; 2000 Oct; 43(10):2307-15. PubMed ID: 11037891
    [Abstract] [Full Text] [Related]

  • 32. Determination of healing response by immunostimulant therapy (levamisole) in cutaneous leishmaniasis.
    Makled M, Rifaat M, Azab M, Makhlouf S, El-Missery A, Khalil N.
    Chemioterapia; 1987 Jun; 6(2 Suppl):214-6. PubMed ID: 3509936
    [No Abstract] [Full Text] [Related]

  • 33. Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children.
    Donia AF, Amer GM, Ahmed HA, Gazareen SH, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA.
    Pediatr Nephrol; 2002 May; 17(5):355-8. PubMed ID: 12042893
    [Abstract] [Full Text] [Related]

  • 34. Antibody-dependent direct cytotoxicity of human lymphocytes. I. Studies on peripheral blood lymphocytes and sera of patients with systemic lupus erythematosus.
    Scheinberg MA, Cathcart ES.
    Clin Exp Immunol; 1976 May; 24(2):317-22. PubMed ID: 1084243
    [Abstract] [Full Text] [Related]

  • 35. B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE.
    Iwata S, Saito K, Tokunaga M, Tanaka Y.
    Ann Rheum Dis; 2012 Oct; 71(10):1749-50. PubMed ID: 22586167
    [No Abstract] [Full Text] [Related]

  • 36. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases.
    Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y.
    J Rheumatol; 1993 Mar; 20(3):495-8. PubMed ID: 8478856
    [Abstract] [Full Text] [Related]

  • 37. Stimulating and differentiation factors for human B lymphocytes in systemic lupus erythematosus.
    Martinez-Cordero E, Alcocer-Varela J, Alarcon-Segovia D.
    Clin Exp Immunol; 1986 Sep; 65(3):598-604. PubMed ID: 3490941
    [Abstract] [Full Text] [Related]

  • 38. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.
    Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y.
    Arthritis Rheum; 2005 Jun; 52(6):1676-83. PubMed ID: 15934077
    [Abstract] [Full Text] [Related]

  • 39. [T- and B-lymphocytes in the so-called collagenoses].
    Standhofer M, Fritz J, Grond K, Klein G.
    Z Rheumatol; 1975 Jun; 34(11-12):418-24. PubMed ID: 1082214
    [Abstract] [Full Text] [Related]

  • 40. Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus.
    Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, Takabayashi K, Takahashi H, Yoshida S, Taniguchi M, Saito Y, Iwamoto I.
    J Rheumatol; 2001 Feb; 28(2):275-83. PubMed ID: 11246661
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.